News
CERT
12.18
+9.83%
1.09
Certara price target raised to $11 from $7 at Baird
TipRanks · 54m ago
Certara price target raised to $12 from $9 at Barclays
TipRanks · 2h ago
Certara (CERT) Q3 Profit Rebound Leaves The Stock Looking Fully Valued
Simply Wall St · 5h ago
Certara, Inc. Reports Third Quarter 2026 Financial Results and Appoints Chief Product Officer
NASDAQ · 15h ago
Certara price target raised to $12 from $8 at BMO Capital
TipRanks · 18h ago
Certara price target raised to $13 from $11 at Leerink
TipRanks · 18h ago
Certara Q3 2026 Earnings Call Transcript
Benzinga · 22h ago
Certara beats top-line estimates; updates FY26 outlook
Seeking Alpha · 1d ago
Certara Narrows FY2026 Adj EPS Guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 Est; Revenue for 2026 FY is expected to be up by 2% to 3% YoY
Benzinga · 1d ago
Certara Q3 2026 Earnings Preview
Seeking Alpha · 1d ago
Weekly Report: what happened at CERT last week (1026-1030)?
Weekly Report · 4d ago
Weekly Report: what happened at CERT last week (1019-1023)?
Weekly Report · 10/26 10:05
Weekly Report: what happened at CERT last week (1012-1016)?
Weekly Report · 10/19 10:05
Keybanc Maintains Overweight on Certara, Raises Price Target to $12
Benzinga · 10/16 13:17
Certara price target raised to $12 from $9 at KeyBanc
TipRanks · 10/16 11:36
KeyBanc Sticks to Their Buy Rating for Certara (CERT)
TipRanks · 10/16 09:16
Certara: Software Bookings Are Improving, But Cash Flow Has Yet To Follow
Seeking Alpha · 10/15 13:12
Certara Is Maintained at Buy by TD Cowen
Dow Jones · 10/13 16:52
TD Cowen Maintains Buy on Certara, Raises Price Target to $11
Benzinga · 10/13 16:42
Certara price target raised to $11 from $9 at TD Cowen
TipRanks · 10/13 12:55
More
Webull provides a variety of real-time CERT stock news. You can receive the latest news about Certara, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CERT
Certara, Inc. is a provider of biosimulation science, technology, and consulting services for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical and biotech industry. The Company's proprietary biosimulation platforms are built on biology, chemistry, and pharmacology principles with proprietary mathematical algorithms that model how medicines and diseases behave in the body. It has developed scientifically-based solutions for the collection, standardization, validation, storage, and analysis of the preclinical, clinical and evidence data needed for MIDD. These data solutions are used internally and industry-wide by life sciences companies. The Company applies AI capabilities within established modeling environments and under the supervision of experienced scientists and regulatory experts. Its modeling platforms and curated datasets position it to incorporate emerging AI techniques in a controlled and scientifically rigorous manner.